Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Smoothened Homolog (Protein Gx or SMO) Products under Development by Stage of Development | 8 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Products under Development by Therapy Area | 9 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Products under Development by Indication | 10 | 2 |
| Smoothened Homolog (Protein Gx or SMO) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Products under Development by Companies | 14 | 3 |
| Smoothened Homolog (Protein Gx or SMO) Products under Development by Universities/Institutes | 17 | 2 |
| Smoothened Homolog (Protein Gx or SMO) Therapeutics Assessment | 19 | 6 |
| Assessment by Monotherapy/Combination Products | 19 | 1 |
| Assessment by Mechanism of Action | 20 | 1 |
| Assessment by Route of Administration | 21 | 2 |
| Assessment by Molecule Type | 23 | 2 |
| Smoothened Homolog (Protein Gx or SMO) Companies Involved in Therapeutics Development | 25 | 9 |
| BeiGene, Ltd. | 25 | 1 |
| F. Hoffmann-La Roche Ltd. | 26 | 1 |
| Ignyta, Inc. | 27 | 1 |
| Mayne Pharma Group Limited | 28 | 1 |
| Novartis AG | 29 | 1 |
| PellePharm, Inc. | 30 | 1 |
| Pfizer Inc. | 31 | 1 |
| Redx Pharma Plc | 32 | 1 |
| Stemline Therapeutics, Inc. | 33 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Drug Profiles | 34 | 25 |
| glasdegib Drug Profile | 34 | 2 |
| GSA-10 Drug Profile | 36 | 1 |
| itraconazole Drug Profile | 37 | 3 |
| LEQ-506 Drug Profile | 40 | 1 |
| Monoclonal Antibody to Inhibit Smoothened for Oncology Drug Profile | 41 | 1 |
| patidegib hydrochloride Drug Profile | 42 | 1 |
| RDX-001 Drug Profile | 43 | 1 |
| Small Molecules to Antagonize Smoothened (Smo) Receptor for Cancer Drug Profile | 44 | 1 |
| Small Molecules to Inhibit Smoothened Homolog for Oncology Drug Profile | 45 | 1 |
| sonidegib phosphate Drug Profile | 46 | 5 |
| taladegib Drug Profile | 51 | 2 |
| vismodegib Drug Profile | 53 | 6 |
| Smoothened Homolog (Protein Gx or SMO) Dormant Projects | 59 | 4 |
| Smoothened Homolog (Protein Gx or SMO) Discontinued Products | 63 | 1 |
| Smoothened Homolog (Protein Gx or SMO) Featured News &Press Releases | 64 | 13 |
| Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting | 64 | 1 |
| Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS | 64 | 1 |
| Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial | 65 | 1 |
| Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment | 65 | 1 |
| Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients | 66 | 2 |
| Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer | 68 | 1 |
| May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting | 68 | 1 |
| May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer | 69 | 1 |
| Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say | 70 | 2 |
| Mar 02, 2015: Basal Cell Carcinoma Drug Encourages Both Cancer Regression and Loss of Taste in Patients | 72 | 1 |
| Dec 16, 2014: HedgePath Pharmaceuticals Receives IND Clearance to Commence Development of its Proposed Cancer Treatment | 73 | 1 |
| Nov 18, 2014: HedgePath Pharmaceuticals Files IND Application | 73 | 1 |
| Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 | 74 | 1 |
| Jun 23, 2014: Curis Announces Investigational New Drug Application Filing by Roche to Initiate a Phase II Study of Erivedge (vismodegib) in Idiopathic Pulmonary Fibrosis | 75 | 1 |
| Jun 01, 2014: Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma | 75 | 2 |
| Appendix | 77 | 2 |
| Methodology | 77 | 1 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 77 | 1 |
| Expert Panel Validation | 77 | 1 |
| Contact Us | 77 | 1 |
| Disclaimer | 78 | 1 |